Latest Advances in Lung Cancer Research

A novel nanoparticle vaccine halts lung cancer spread in mice by training the immune system to attack tumor cells, showing promise for post-surgery cancer prevention.

UCLA researchers received a $6 million grant to refine a liquid biopsy blood test for early, accurate lung cancer detection and treatment guidance.

Johnson & Johnson’s Rybrevant shows comparable efficacy to AstraZeneca’s Tagrisso in advanced NSCLC, suggesting potential as an initial treatment option.

Experimental gene therapy drug HPN328 is being tested with Tecentriq in a trial to enhance immune response against small cell lung cancer.

Adding atezolizumab and tiragolumab to chemotherapy may improve survival in extensive stage small cell lung cancer, with further research needed.

Fred Hutchinson Cancer Center received a $30 million NCI grant to enhance cancer research and support vital services for the next five years.

At the 2023 World Conference, lung cancer advocacy triumphed with a 25% funding boost for the Lung Cancer Research Program, thanks to strategic lobbying and a unified advocacy platform.

Scientists discover new link between air pollution and lung cancer, finding tiny particles trigger genetic changes, leading to new prevention and treatment opportunities.

A new study found staggering differences in the toll of death among Black and White Americans over a 22-year period. According to the researchers, while all racial groups saw decreases in death rates over that time, rates for Black people remained unchanged.

The researchers hope the findings of ‘ever-changing’ nature of lung cancer could help doctors to tailor treatments for individual patients.

Research study shows pacritinib has the ability to selectively target in squamous cell but does not impact normal glucose metabolism.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.